Press Release 23 May 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “the Company”)
Sativa invests C$ 0.2 million in Canadian-based Rapid Dose Therapeutics Inc. which owns QuickStrip™ oral technology for medicinal cannabis use
Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, has subscribed to, through a private placement which may or may not precede an IPO, 400,000 shares at C$ 0.50 per share, at a cost of C$ 0.2 million cash, in Toronto-based Pharma-Tech company, Rapid Dose Therapeutics Inc. (“RDT”).
RDT has its own patent-pending proprietary QuickStrip™ technology, a fast-dissolving strip that is placed on or under the tongue, or inside the cheek, then enters directly in to the recipient’s system, mimicking an injection path. Pharmaceuticals, emulsified oils and over-the-counter medicines are used in RDT’s proprietary RDMx mixture technology, which is sold across North America.
Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “RDT’s technology delivers medicinal cannabis bypassing the normal oral or inhaler delivery and, as such, is an exceptional way of ingesting the therapy, is easy to administer, provides a consistent and rapid dose, and is likely to improve patient outcomes.
“The dynamic medicinal cannabis market in Canada has allowed RDT to develop this CBD product to be absorbed directly in to a person’s system.”
Mark Upsdell, Chief Executive Officer of Rapid Dose Therapeutics, said: “Our proprietary formulation for the mixture of various medicines and pharmaceuticals to be administered through our QuickStrip™ technology, has led to RDT using CBD medicinal cannabis in QuickStrip™.
“We are delighted to have entered in to this new relationship with Sativa. RDT looks forward working together with Sativa in this fast developing market to unlock the potential for our products in the UK and Europe.”
– Ends –
For more information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
+44 (0) 20 7469 4630
Notes to Editors
Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: